These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 2167147)

  • 1. Functional and phenotypic characteristics of recombinant interleukin-2 or T-cell growth factor-activated splenic lymphoid cells from patients with gastric or hepatocellular carcinoma.
    Ebihara T; Fukao K; Koyama S
    Cancer; 1990 Sep; 66(5):923-9. PubMed ID: 2167147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential activation of lymphokine-activated killer cells with different surface phenotypes by cultivation with recombinant interleukin 2 or T-cell growth factor in gastric cancer patients.
    Koyama S; Ebihara T; Fukao K; Osuga T
    Jpn J Cancer Res; 1989 Feb; 80(2):150-7. PubMed ID: 2498249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine-activated suppressor (LAS) cells in patients with gastric carcinoma.
    Ebihara T; Koyama S; Fukao K; Osuga T
    Cancer Immunol Immunother; 1989; 28(3):218-24. PubMed ID: 2522349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
    Fox BA; Rosenberg SA
    Cancer Immunol Immunother; 1989; 29(3):155-66. PubMed ID: 2786456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB; Itoh K; Balch CM
    J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumour cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma.
    Koyama S; Fukao K
    J Cancer Res Clin Oncol; 1994; 120(4):240-7. PubMed ID: 7904606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and phenotypic characteristics of effusion-associated lymphoid cells cultured in the presence of either recombinant interleukin 2 or T-cell growth factor from malignant pleural and peritoneal effusions in patients with advanced carcinoma.
    Ebihara T; Koyama S
    Tohoku J Exp Med; 1990 Sep; 162(1):49-63. PubMed ID: 2077678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
    Lynch DH; Miller RE
    J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro induction of cytotoxic activity against carcinomatous pleural or peritoneal lymphoid cells cultivated with cytokines, and an immunological phenotypic analysis of the effector cells].
    Ebihara T; Koyama S
    Gan No Rinsho; 1990 Apr; 36(5):604-10. PubMed ID: 2325266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
    Zhai YF; Esselman WJ; Oakley CS; Chang CC; Welsch CW
    Cancer Immunol Immunother; 1992; 35(4):237-45. PubMed ID: 1511458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of lymphokine-activated killer (LAK) cell activity from malignant peritoneal effusions.
    Chao TY; Hwang WS; Yeh MY
    Proc Natl Sci Counc Repub China B; 1995 Apr; 19(2):92-8. PubMed ID: 7624448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological responses against an autologous human hepatocellular carcinoma cell line.
    Usuda S; Yoshizawa K; Yabu K; Kiyosawa K
    J Gastroenterol Hepatol; 1993; 8(6):517-23. PubMed ID: 8280838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer (LAK) cells. VI. NK1.1+, CD3+ LAK effectors are derived from CD4-, CD8-, NK1.1- precursors.
    Ballas ZK; Rasmussen W
    Cell Immunol; 1991 May; 134(2):296-313. PubMed ID: 1827045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of human lymphokine-activated killer cell activity in splenic lymphocytes by the combination of low-dose interleukin 2 plus interleukin 3.
    Okuno K; Ohnishi H; Shilayama Y; Hirohata T; Ozaki M; Yasutomi M
    Mol Biother; 1992 Jun; 4(2):83-6. PubMed ID: 1515099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of basic procedures for adoptive immunotherapy for gastric cancer.
    Fujimoto T; Omote K; Mai M; Natsuume-Sakai S
    Biotherapy; 1992; 5(2):153-63. PubMed ID: 1524956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
    Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
    J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gelatin sponge model of effector recruitment: tumoricidal activity of adherent and non-adherent lymphokine-activated killer cells after culture in interleukin-2.
    Akporiaye ET; Barbieri CA; Stewart CC; Bender JG
    J Leukoc Biol; 1991 Feb; 49(2):189-96. PubMed ID: 1991999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma.
    Koyama S
    J Cancer Res Clin Oncol; 1997; 123(9):478-84. PubMed ID: 9341896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.